GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: GlobeNewswire
VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last month, ushering in a new clinical paradigm for patients with historically resistant tumors [1]. Separately, the agency fast-tracked an experimental pancreatic cancer therapy based on early trial results showing tumors shrinking in nearly a third of patients[2]. These regulatory milestones position immunotherapy platforms capable of unlocking durable responses across multiple gastrointestinal malignancies as the next wave of commercial opportunity, drawing attention to developers advancing combination regimens in colorectal, pancreatic, and anal cancers. Among companies positioned to capitalize on this shift are Oncolytics Biotech Inc. (NASDAQ: ONCY), Agenus Inc. (NASDAQ: AGEN), Cardiff Oncology, Inc. (NASDAQ: CRDF), Exelixis, Inc. (NASDAQ: EXEL), and Gilead Sciences, Inc
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era [Canadian Business Journal (Canada)]Canadian Business Journal
- Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Oncolytics Biotech (NASDAQ:ONCY) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to NevadaBusiness Wire
- THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality [Canadian Business Journal (Canada)]Canadian Business Journal
ONCY
Earnings
- 11/12/25 - Miss
ONCY
Sec Filings
- 12/10/25 - Form EFFECT
- 12/10/25 - Form 6-K
- 12/9/25 - Form 424B3
- ONCY's page on the SEC website